Evidence map›Paper›PMID 29956006›Full record

ArticlePediatric nephrology (Berlin, Germany)2018

Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.

Mark R Hanudel, Marciana Laster, Georgina Ramos, Barbara Gales, Isidro B Salusky

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric nephrology (Berlin, Germany), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mark R HanudelDepartment of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, MDCC A2-383, Los Angeles, CA, 90095-1752, USA. mhanudel@mednet.ucla.edu.ORCID 0000-0002-5886-8078
Marciana LasterDepartment of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, MDCC A2-383, Los Angeles, CA, 90095-1752, USA.
Georgina RamosDepartment of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, MDCC A2-383, Los Angeles, CA, 90095-1752, USA.
Barbara GalesDepartment of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, MDCC A2-383, Los Angeles, CA, 90095-1752, USA.
Isidro B SaluskyDepartment of Pediatrics, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, MDCC A2-383, Los Angeles, CA, 90095-1752, USA.
University of California, Los Angeles · US

Funding

Phosphate binder therapy and chronic kidney disease in childrenU01DK122013 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ISIDRO B. SALUSKY · 2020 to 2026
$10.8M
Translational Research Training in Pediatric NephrologyT32DK104687 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SALUSKY, ISIDRO B. · 2015 to 2019
$879k
Regulation of Fibroblast Growth Factor 23 by Iron and Anemia in Chronic Kidney DiseaseK08DK111980 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HANUDEL, MARK ROBERT · 2016 to 2019
$758k
NIDDK NIH HHS K08 DK111980NIDDK NIH HHS K08-DK111980NIDDK NIH HHS T32 DK104687NIDDK NIH HHS T32-DK104687NIDDK NIH HHS U01 DK122013
6 · The paper itself

Abstract

backgroundFerric citrate, an iron-based phosphate binder, has been shown to improve both hyperphosphatemia and iron deficiency in adult chronic kidney disease patients, but its use in the pediatric dialysis population has not been described.

methodsThis is a retrospective analysis of 11 unselected pediatric dialysis patients who received ferric citrate as a phosphate binder between 2015 and 2017. Time-averaged laboratory values were compared pre- and post-ferric citrate initiation using the Wilcoxon signed-rank test.

resultsThe median age of this cohort was 13 years old (range 4-17 years old). Five patients were on hemodialysis, and six patients were on peritoneal dialysis. The median duration of ferric citrate therapy was 214 days (range 39-654 days), with a median time-averaged ferric citrate dose of 3.5 tablets per day (range 1.5-8.4 tablets per day). Compared to the pre-ferric citrate period, ferric citrate treatment was associated with decreased serum phosphate (6.5 to 5.2 mg/dl, p = 0.014), decreased phosphate age-related standard deviation score (SDS) (2.3 to 0.9, p = 0.019), increased transferrin saturation (26 to 34%, p = 0.049), increased ferritin (107 to 230 ng/ml, p = 0.074), and maintenance of hematocrit.

conclusionsIn pediatric dialysis patients, ferric citrate may be able to concurrently lower phosphate levels and treat iron deficiency. However, larger studies are needed to further evaluate safety and efficacy in the pediatric chronic kidney disease population.

Indexed as

Off-Label UseAdolescentAnemia, Iron-DeficiencyChildChild, PreschoolDose-Response Relationship, DrugFemaleFerric CompoundsHumansHyperphosphatemiaMalePhosphatesRenal DialysisRenal Insufficiency, ChronicRetrospective StudiesTreatment Outcomeferric citrateFerric CompoundsPhosphatesCKD-MBDDialysisFerric citrateIron deficiencyPediatricPhosphate

Identifiers

PMID29956006
PMCPMC6146015
OpenAlexW2810468169

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.